Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
Purpose: Lutetium labelled prostate-specific membrane antigen radioligand therapy (Lu-PSMA RLT) has shown pleasing early results in management of high-volume metastatic castration resistant prostate cancer (mCRPC), but its role in the early treatment of men with only lymph node metastasis (LNM) is u...
Enregistré dans:
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Korean Urological Association
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/f09385922af24e11a3b719c3f5dde7df |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|